Platelet-activating factor and bacteremia-induced pulmonary hypertension

Journal of Surgical Research

Volumn 88, Issue 2, 2000, Pages 173-180

  Clavijo, Leonardo C ^a   Carter, Mary B ^a   Matheson, Paul J ^a   Wills Frank, Lisa A ^a   Wilson, Mark A ^a   Wead, William B ^a   Garrison, R Neal ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Endothelin 1; Escherichia coli; Gram negative sepsis; Lung injury; Neutrophil; Nitric oxide; Platelet activating factor; Pulmonary artery catheterization; Pulmonary edema; Rat

Indexed keywords

APAFANT; ENDOTHELIN 1; MYELOPEROXIDASE; NITRIC OXIDE; SODIUM CHLORIDE; THROMBOCYTE ACTIVATING FACTOR; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; THROMBOCYTE ACTIVATING FACTOR RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL GAS; ARTICLE; BACTEREMIA; BLOOD VESSEL PERMEABILITY; BLOOD VESSEL TONE; BREATHING RATE; CONTROLLED STUDY; ESCHERICHIA COLI; HEART RATE; HEMOCONCENTRATION; HYPOXEMIA; LEUKOCYTE ACTIVATION; LUNG ARTERY PRESSURE; LUNG INJURY; LUNG PARENCHYMA; LUNG VASCULAR RESISTANCE; MALE; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAT; VASOCONSTRICTION;

EID: 0033969869     PISSN: 00224804     EISSN: None     Source Type: Journal    
DOI: 10.1006/jsre.1999.5748     Document Type: Article

References (41)

1. Bussolino F., Porcellini M. G., Varese L., Bosia A. Intravascular release of platelet-activating factor in children with sepsis. Thromb. Res. 48:1987;619.
2. Graham R. M., Stephens C. J., Silvester W., Leong L. L., Strum M. J., Taylor R. R. Plasma degradation of platelet-activating factor in severely ill patients with clinical sepsis. Crit. Care Med. 22:1994;204.
3. Anderson B. O., Bensard D. D., Harken A. H. The role of platelet-activating factor and its antagonist in shock, sepsis and multiple organ failure. Surgery. 172:1991;415.
4. Fink A., Geva D., Zung A., Konichezky S., Eliraz A., Bentwich Z. Adult respiratory distress syndrome: Roles of leukotriene C4 and platelet-activating factor. Crit. Care Med. 18:1990;905.
5. Chang S., Fedderson C. O., Henson P. M., Voekel N. F. Platelet-activating factor mediates hemodynamic changes and lung injury in endotoxin-treated rats. J. Clin. Invest. 79:1987;1498.
6. Olson N. C., Joyce P. B., Fleisher L. N. Mono-hydroxyeicosatetraenoic acids during porcine endotoxemia: Effect of a platelet-activating factor receptor antagonist. Lab. Invest. 63:1989;221.
7. Carter M. B., Wilson M. A., Wead W. B., Garrison R. N. Platelet-activating factor mediates pulmonary macromolecular leak following intestinal ischemia-reperfusion. J. Surg. Res. 60:1996;403.
8. Filep J., Herman F., Braquet P., Mozes T. Increased levels of platelet-activating factor in blood following intestinal ischemia in the dog. Biochem. Biophys. Res. Commun. 158:1989;353.
9. Lewis J. C., O'Flaherty J. T., McCall C. E., Wykle R. L., Bond M. G. Platelet-activating factor effects on pulmonary ultrastructure in rabbits. Exp. Mol. Pathol. 38:1983;100.
10. Bussolino F., Camussi G., Aglietta M., Braquet P., Bosia A., Pescarmona G., Sanavio F., D'Urso N., Marchisio P. C. Human endothelial cells are target for platelet-activating factor. J. Immunol. 139:1987;2439.
11. Gao Y., Zhou H., Raj U. PAF induces relaxation of pulmonary arteries but contraction of pulmonary veins in the ferret. Am. Phys. 269:1985;H704.
12. Clavijo, L. C, Carter, M. B, Matheson, P. J, Wilson, M. A, Wead, W. B, and, Garrison, R. N. Platelet-activating factor increases pulmonary vascular permeability without increasing pulmonary artery pressure. Submitted for publication.
13. Laurindo F. R. M., Goldstein R. E., Davenport N. J., Ezra D., Feuerstein G. Z. Mechanisms of hypotension produced by platelet-activating factor. J. Appl. Physiol. 66:1989;2681.
14. McMurtry I. F., Morris K. G. Platelet-activating factor causes pulmonary vasodilation in the rat. Am. Rev. Respir. Dis. 134:1986;757.
15. Spain D. A., Wilson M. A., Garrison R. N. The role of nitric oxide in regulation of the rat small intestinal microcirculation during bacteremia. Shock. 2:1994;41.
16. Herget J., Paleček F. Pulmonary arterial blood pressure in closed chest rats: Changes after catecholamines, histamine and serotonin. Arch. Int. Pharmacodyn. 198:1972;107.
17. Misko T. P., Schilling R. J., Salvemini D., Moore W. M., Currie M. G. A fluorometric assay for the measurement of nitrite in biological samples. Anal. Biochem. 214:1993;11.
18. Matheson P. J., Spain D. A., Harris P. D., Garrison R. N., Wilson M. A. Glucose and glutamine gavage increase portal vein nitric oxide metabolite levels via adenosine A2b activation. J. Surg. Res. 83:1999;105.
19. Grisham M. B., Benoit J. N., Granger D. N. Assessment of leukocyte involvement during ischemia and reperfusion of intestine. Methods Enzymol. 186:1990;729.
20. Schierwagen C., Bylund-Fellenius A.-C., Lundberg C. Improved method for quantitation of tissue PMN accumulation measured by myeloperoxidase activity. J. Pharmacol. Methods. 23:1990;179.
21. Bloomfield G. L., Ridings P. C., Blocher C. R., Fisher B. J., Sugerman H. J., Nagamoto H., Fowler A. A. OPC-6535, a superoxide anion production inhibitor, attenuates acute lung injury. J. Surg. Res. 72:1997;70.
22. Ridings P. C., Hollowway S., Gbloomfield G. L., Phillips M. L., Fisher B. J., Blocher C. R., Sugarman H. J., Fowler A. A. Protective role of synthetic sialylated oligosaccharide in sepsis-induced acute lung injury. J. Appl. Physiol. 82:1997;644.
23. Welty-Wolf K. E., Carraway M. S., Huang Y. C. T., Simonson S. G., Kantrow S. P., Piantadosi C. A. Bacterial priming increases lung injury in gram-negative sepsis. Am. J. Respir. Crit. Care Med. 158:1998;610.
24. Carraway M. S., Welty-Wolf K. E., Kantrow S. P., Huang Y. C. T., Simonson S. G., Que L. G., Kishimoto T. K., Piantadosi C. A. Antibody to E- and L-selectin does not prevent lung injury or mortality in septic baboons. Am. J. Respir. Crit. Care Med. 157:1998;938.
25. Bar-Natan M. F., Wilson M. A., Spain D. A., Garrison R. N. Platelet-activating factor and sepsis-induced small intestinal microvascular hypoperfusion. J. Surg. Res. 58:1995;38.
26. Miotla J. M., Jeffery P. K., Hellewell P. G. Platelet-activating factor plays a pivotal role in the induction of experimental lung injury. Am. J. Respir. Cell Mol. Biol. 18:1998;197.
27. G-monomethyl-L-arginine or indomethacin. J. Pharmacol. Exp. Ther. 272:1995;452.
28. Buttery L. D. K., Evans T. J., Springall D. R., Carpenter A., Cohen J., Polak J. M. Immunochemical localization of inducible nitric oxide synthase in endotoxin-treated rats. Lab. Invest. 71:1994;755.
29. Petros, A, Bennett, D, and, Vallance, P. Effect of nitric oxide synthase inhibitors on hypotension in patients with septic shock, Lancet, 338, 1557, 1991.
30. Chou M. C., Wilson M. A., Spain D. A., Hadjiminas D., Anderson G. L., Cheadle W. G., Garrison R. N. Endothelin-1 expression in the small intestine during chronic peritonitis. Shock. 4:1995;411.
31. Wilson M. A., Steeb G. D., Garrison R. N. Endothelins mediate intestinal hypoperfusion during bacteremia. Shock. 55:1993;168.
32. Bloom I. T., Bentley F. R., Wilson M. A., Garrison R. N. In vivo effects of endothelin on the renal microcirculation. J. Surg. Res. 54:1993;274.
33. Spain D. A., Wilson M. A., Bar-Natan M. F., Garrison R. N. Nitric oxide synthase inhibition aggravates intestinal microvascular vasoconstriction and hypoperfusion of bacteremia. J. Trauma. 36:1994;720.
34. Gryglewski R. J., Wolkow P. P., Uracz W., Janowska E., Bartus J. B., Balbatun O., Patton S., Brovkovych V., Malinski T. Protective role of pulmonary nitric oxide in the acute phase of endotoxemia in rats. Circ. Res. 82:1998;819.
35. Meyer J., Lentz C. W., Stothert J. C., Traber L. D., Herndon D. N., Traber D. L. Effects of nitric oxide synthesis inhibition in hyperdynamic endotoxemia. Crit. Care Med. 22:1994;306.
36. Repine J. E., Bowman M., Tate R. M. Neutrophils and lung edema. Chest. 81:1982;475.
37. Tate R. M., Repine J. E. Neutrophils and the adult respiratory distress syndrome. Am. Rev. Respir. Dis. 128:1990;532.
38. Sheridan B. C., McIntyre R. C. Jr., Moore E. E., Meldrum D. R., Agrafojo J., Fullerton D. A. Neutrophils mediate pulmonary vasomotor dysfunction in endotoxin-induced acute lung injury. J. Trauma. 42:1997;391.
39. Sheridan B. C., McIntyre R. C., Agrafojo J., Meldrum D. R., Meng X., Fullerton D. A. Neutrophil depletion attenuates endotoxin-induced dysfunction of cGMP-mediated pulmonary vasorelaxation. Am. J. Phys. 271:1996;L820.
40. Spapen H., Zhang H., Verhaeghe V., Rogiers P., Cabral A., Vincent J. L. Treatment with a platelet-activating factor antagonist has little protective effects during endotoxic shock in the dog. Shock. 8:1997;200.
41. Dhainaut, J.-F. A, Tenaillon, A, Tulzo, Y. L, Schlemmer, B. S, Solet, J.-P, Wolff, M, Holzapfel, L, Zeni, F, Dreyfuss, D, Mira, J.-P, Vathaire, F. D, Guinot, P, and, the BN 52021 Sepsis Study Group, Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: A randomized, double-blind, placebo-controlled, multicenter clinical trial, Crit. Care Med. 22, 1720.